Development and Validation of a Machine Learning-Based Model Used for Predicting Hepatocellular Carcinoma Risk in Patients with Hepatitis B-Related Cirrhosis: A Retrospective Study
Yixin Hou,Jianguo Yan,Ke Shi,Xiaoli Liu,Fangyuan Gao,Tong Wu,Peipei Meng,Min Zhang,Yuyong Jiang,Xianbo Wang
DOI: https://doi.org/10.2147/ott.s444536
IF: 4
2024-03-24
OncoTargets and Therapy
Abstract:Yixin Hou, 1, &ast Jianguo Yan, 2, &ast Ke Shi, 1, 3, &ast Xiaoli Liu, 1 Fangyuan Gao, 1 Tong Wu, 1 Peipei Meng, 1 Min Zhang, 2 Yuyong Jiang, 1 Xianbo Wang 1 1 Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China; 2 People's Liberation Army Fifth Medical Center, Beijing, 100039, People's Republic of China; 3 Department of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xianbo Wang, Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, People's Republic of China, Email Min Zhang, People's Liberation Army Fifth Medical Center, Beijing, 100039, People's Republic of China, Email Object: Our objective was to estimate the 5-year cumulative risk of HCC in patients with HBC by utilizing an artificial neural network (ANN). Methods: We conducted this study with 1589 patients hospitalized at Beijing Ditan Hospital of Capital Medical University and People's Liberation Army Fifth Medical Center. The training cohort consisted of 913 subjects from Beijing Ditan Hospital of Capital Medical University, while the validation cohort comprised 676 subjects from People's Liberation Army Fifth Medical Center. Through univariate analysis, we identified factors that independently influenced the occurrence of HCC, which were then used to develop the ANN model. To evaluate the ANN model, we assessed its predictive accuracy, discriminative ability, and clinical net benefit using metrics such as the area under the receiver operating characteristic curve (AUC), concordance index (C-index), calibration curves. Results: In total, we included nine independent risk factors in the development of the ANN model. Remarkably, the AUC of the ANN model was 0.880, significantly outperforming the AUC values of other existing models including mPAGE-B (0.719) (95% CI 0.670– 0.768), PAGE-B (0. 710) (95% CI 0.660– 0.759), FIB-4 (0.693) (95% CI 0.640– 0.745), and Toronto hepatoma risk index (THRI) (0.705) (95% CI 0.654– 0.756) (p< 0.001 for all). The ANN model effectively stratified patients into low, medium, and high-risk groups based on their 5-year In the training cohort, the positive predictive value (PPV) for low-risk patients was 26.2% (95% CI 25.0– 27.4), and the negative predictive value (NPV) was 98.7% (95% CI 95.2– 99.7). For high-risk patients, the PPV was 54.7% (95% CI 48.6– 60.7), and the NPV was 91.6% (95% CI 89.4– 93.4). These findings were validated in the independent validation cohort. Conclusion: The ANNs model has good individualized prediction performance and may be helpful to evaluate the probability of the 5-year risk of HCC in patients with HBC. Keywords: machine learning-based model, hepatocellular carcinoma, risk, hepatitis B-related cirrhosis Hepatocellular carcinoma (HCC) was the third leading cause of cancer mortality. 1 Hepatitis B-related cirrhosis (HBC) is a well-known risk factor for HCC and accounts for 50%-80% of HCC cases worldwide. 2,3 Given the increasing incidence of HCC related to HBC, managing patients with HBC in an ambulatory setting is crucial. Although the current first-line oral nucleos(t)ide analogues (NAs), such as entecavir (ETV) or tenofovir disoproxil fumarate (TDF), can effectively inhibit hepatitis B virus (HBV) replication, HCC can still develop in chronic hepatitis B (CHB) patients undergoing NA treatment. 2,4,5 A 10-year follow-up study conducted in Europe revealed the occurrence of new HCC cases even after more than 5 years of NA treatment. 6 Thus, it is essential to stratify the risk of HCC in patients with HBC. Evidence suggests that large-scale community-wide ultrasonography (USG) screening for HCC can significantly reduce HCC-related mortality 2,7 According to a updated meta-analysis about 24% of the patients with cirrhosis adhered to regular HCC screening prior to their HCC diagnoses. 8 Current expert guidelines recommend HCC screening for all patients with HBC, including chronic carriers of HBV, particularly Asian men aged 40 years and women aged 50 years. 9 However, even with these guidelines, a considerable number of individuals at risk below these age limits still develop HCC. 10 Consequently, there is a need for an stratify HCC risks prediction model specifically designed for HBC patients to classify the population into different risk categor -Abstract Truncated-
oncology,biotechnology & applied microbiology